PD-L1 and Survival in Solid Tumors: A Meta-Analysis.

PD-L1 and Survival in Solid Tumors: A Meta-Analysis.

Numerous agents targeting PD-L1/PD-1 check-point are in clinical development. However, the correlation between PD-L1 expression and prognosis of solid tumor is still in controversial. Here, we elicit a systematic review and meta-analysis to investigate the potential value of PD-L1 in the prognostic...

Full description

Bibliographic Details
Main Authors:	Pin Wu, Dang Wu, Lijun Li, Ying Chai, Jian Huang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4483169?pdf=render

Similar Items

The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
by: Run-Cong Nie, et al.
Published: (2020-01-01)

Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
by: Weng YM, et al.
Published: (2018-10-01)

Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
by: Chunyan Yue, et al.
Published: (2018-07-01)

PD-1/PD-L1 immunotherapy blockade in solid tumors: role of PD-1/PD-L1 in cancer disease progression
by: Li, Vivian
Published: (2021)

Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
by: Hongmei Liu, et al.
Published: (2020-10-01)

The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis
by: Zhihua Si, et al.
Published: (2019-09-01)

The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
by: Yuan Tian, et al.
Published: (2020-02-01)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
by: Xianjie Jiang, et al.
Published: (2019-01-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.
by: Tiancheng Zhao, et al.
Published: (2017-01-01)

The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials
by: Siyao Deng, et al.
Published: (2019-09-01)

A novel signature based on pairwise PD‐1/PD‐L1 signaling pathway genes for predicting the overall survival in patients with hepatocellular carcinoma
by: Enfa Zhao, et al.
Published: (2021-05-01)

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
by: Wagner LM, et al.
Published: (2017-04-01)

The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis
by: Bi‐Cheng Wang, et al.
Published: (2019-10-01)

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
by: Fan Y, et al.
Published: (2016-10-01)

Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
by: Shixue Chen, et al.
Published: (2021-04-01)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
by: Xiao-Jun Guo, et al.
Published: (2021-08-01)

IRE1α regulates macrophage polarization, PD-L1 expression, and tumor survival.
by: Alyssa Batista, et al.
Published: (2020-06-01)

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
by: Jiaxin Zhu, et al.
Published: (2019-06-01)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
by: Jingwei Liu, et al.
Published: (2020-01-01)

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
by: Francesco Spagnolo, et al.
Published: (2021-04-01)

Regulation of PD-L1 expression in the tumor microenvironment
by: Ming Yi, et al.
Published: (2021-01-01)

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors
by: Simon Chowdhury, et al.
Published: (2020-08-01)

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo
by: Qibin Liao, et al.
Published: (2020-11-01)

Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
by: Jiangang Sun, et al.
Published: (2020-09-01)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
by: Yafang Huang, et al.
Published: (2019-05-01)

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis
by: Haoran Liu, et al.
Published: (2020-01-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis
by: SHEN Shijun, et al.
Published: (2021-03-01)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
by: Peng-Fei Wang, et al.
Published: (2017-10-01)

Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis
by: Yuhan Wei, et al.
Published: (2020-01-01)

Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
by: Zhiyang Li, et al.
Published: (2021-03-01)

Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis
by: Yuan Tian, et al.
Published: (2021-05-01)

PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread
by: Tiina Vesterinen, et al.
Published: (2019-08-01)

The Prognostic Value of Decreased LKB1 in Solid Tumors: A Meta-Analysis.
by: Jian Xiao, et al.
Published: (2016-01-01)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
by: Qingyang Lei, et al.
Published: (2020-07-01)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
by: Rawad Elias, et al.
Published: (2018-04-01)

Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
by: Qingyuan Huang, et al.
Published: (2018-12-01)

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
by: Di Lu, et al.
Published: (2019-01-01)

PD-L1 Deficiency within Islets Reduces Allograft Survival in Mice.
by: Dongxia Ma, et al.
Published: (2016-01-01)

Cannot write session to /tmp/vufind_sessions/sess_hekogrdnoih98265rvirjmo2mv